Bioferon

Bioferon is a Turkish biotechnology company dedicated to the development, manufacturing, and commercialization of high-quality biosimilar pharmaceuticals. Established in 2017 and headquartered in Istanbul, the company focuses on expanding patient access to complex biologic therapies in therapeutic areas such as oncology, hematology, and immunology. Bioferon's pipeline includes biosimilar candidates for major blockbuster biologics, including rituximab, bevacizumab, and trastuzumab. The company operates advanced manufacturing facilities designed to meet international regulatory standards, aiming to serve both the domestic Turkish market and regional international markets. Bioferon plays a significant role in the regional effort to localize the production of high-value biotechnological drugs.